Chinese Journal of Mycology 2023, Vol. 18 Issue (4): 370-376.
Previous Articles Next Articles
Received:2022-04-05
Online:2023-08-28
Published:2023-09-02
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: http://cjmycology.smmu.edu.cn:81/Jweb_zgzj/EN/
http://cjmycology.smmu.edu.cn:81/Jweb_zgzj/EN/Y2023/V18/I4/370
| [1] STEWART A G, PATERSON D L. How urgent is the need for new antifungals[J]. Expert Opin Pharmacother, 2021, 22(14):1857-1870. [2] ARASTEHFAR A, DE ALMEIDA JÚNIOR J N, PERLIN D S, et al. Multidrug-resistant Trichosporon species: Underestimated fungal pathogens posing imminent threats in clinical settings[J]. Crit Rev Microbiol, 2021, 47(6):679-698. [3] LAMOTH F, GLAMPEDAKIS E, BOILLAT-BLANCO N, et al. Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients[J]. Clin Microbiol Infect, 2020, 26(12):1706-1708. [4] BARTOLETTI M, PASCALE R, CRICCA M, et al. Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19: A prospective study[J]. Clin Infect Dis, 2021, 73(11):e3606-e3614. [5] JAMES K D, LAUDEMAN C P, MALKAR N B, et al. Structure-activity relationships of a series of echinocandins and the discovery of CD101, a highly stable and soluble echinocandin with distinctive pharmacokinetic properties[J]. Antimicrob Agents Chemother, 2017, 61(2):e01541-01516. [6] PFALLER M A, MESSER S A, RHOMBERG P R, et al. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates[J]. J Antimicrob Chemother, 2016, 71(10):2868-2873. [7] WIEDERHOLD N P, LOCKE J B, DARUWALA P, et al. Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species[J]. J Antimicrob Chemother, 2018, 73(11):3063-3067. [8] MIESEL L, CUSHION MT, ASHBAUGH A, et al. Efficacy of rezafungin in prophylactic mouse models of invasive candidiasis, aspergillosis, and Pneumocystis pneumonia[J]. Antimicrob Agents Chemother, 2021, 65(3):e01992-20. [9] SANDISON T, ONG V, LEE J, et al. Safety and pharmacokinetics of CD101Ⅳ, a novel echinocandin, in healthy adults[J]. Antimicrob Agents Chemother, 2017, 61(2):e01627-01616. [10] ONG V, HOUGH G, SCHLOSSER M, et al. Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin[J]. Antimicrob Agents Chemother, 2016, 60(11):6872-6879. [11] THOMPSON G R, SORIANO A, SKOUTELIS A, et al. Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: The strive trial[J]. Clin Infect Dis,2021, 73(11):e3647-e3655. [12] JIMéNEZ-ORTIGOSA C, PEREZ W B, ANGULO D, et al. De novo acquisition of resistance to SCY-078 in Candida glabrata involves FKS mutations that both overlap and are distinct from those conferring echinocandin resistance[J]. Antimicrob Agents Chemother,2017, 61(9):e00833-17. [13] LAMOTH F, ALEXANDER B D. Antifungal activities of SCY-078(MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates[J]. Antimicrob Agents Chemother,2015, 59(7):4308-4311. [14] DAVIS M R, DONNELLEY M A, THOMPSON G R. Ibrexafungerp: A novel oral glucan synthase inhibitor[J]. Med Mycol,2020, 58(5):579-592. [15] WRING S, BORROTO-ESODA K, SOLON E, et al.SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral SCY-078 in albino and pigmented rats[J]. Antimicrob Agents Chemother,2019, 63(2):e02119-02118. [16] WRING S, MURPHY G, ATIEE G, et al. Clinical pharmacokinetics and drug-drug interaction potential for coadministered SCY-078, an oral fungicidal glucan synthase inhibitor, and tacrolimus[J]. Clin Pharmacol Drug Dev,2019, 8(1):60-69. [17] SPEC A, PULLMAN J, THOMPSON G R, et al. MSG-10: A phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis[J]. J Antimicrob Chemother,2019, 74(10):3056-3062. [18] ALEXANDER B D,Cornely O, PAPPAS P, et al. Effcacy and safety of oral ibrexafungerp in 41 patients with refractory fungal diseases, interim analysis of a phase 3 open-label study (FURI)[J]. Open Forum Infect Dis, 2020, 7(Suppl 1):S642. [19] HOENIGL M CO, KOEHLER P, PAPPAS P G, et al. Outcomes of oral ibrexafungerp in 33 patients with refractory fungal diseases, interim analysis of a phase 3 open-label study (FURI)[C]//31st ECCMID. Vienna:2021. [20] AZIE ND, ROSS C, BREEDT J, et al. Outcomes of oral ibrexafungerp in the treatment of ten patients with candida auris infections, from the cares study[C]//31st ECCMID. Vienna:2021. [21] HELOU S,ANGULO D. A multicenter, randomized, evaluator blinded, active-controlled study to evaluate the safety and efficacy of oral SCY-078vs. oral fuconazole in 96 subjects with moderate to severe vulvovaginal candidiasis[J]. Am J Obstet Gynecol,2017, 217(6):720-721. [22] SCHWEBKE J R, SOBEL R, GERSTEN J K, et al. Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: A phase 3, randomized, controlled superiority trial (vanish 303)[J]. Clin Infect Dis,2022, 74(11):1979-1985. [23] SOBEL R, NYIRJESY P, GHANNOUM M A, et al. Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: A global phase 3, randomised, placebo-controlled superiority study (vanish 306)[J]. Bjog,2022, 129(3):412-420. [24] MURPHY G,DARPO B, MARBURY T. Lack of an effect of SCY-078 a novel antifungal agent on QTc interval in healthy subjects[C]//ASM Microbe. New Orleans:2017. [25] MIYAZAKI M, HORII T, HATA K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds[J]. Antimicrob Agents Chemother,2011, 55(10):4652-4658. [26] ZHAO Y, LEE M H, PADERU P, et al. Significantly improved pharmacokinetics enhances in vivo efficacy of APX001 against echinocandin- and multidrug-resistant Candida isolates in a mouse model of invasive candidiasis[J]. Antimicrob Agents Chemother,2018, 62(10):e00425-00418. [27] HAGER C L, LARKIN E L, LONG L, et al. In vitro and in vivo evaluation of the antifungal activity of APX001A/APX001 against Candida auris[J]. Antimicrob Agents Chemother,2018, 62(3):e02319-17. [28] ZHAO M, LEPAK A J, MARCHILLO K, et al. APX001 pharmacokinetic/pharmacodynamic target determination against aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis[J]. Antimicrob Agents Chemother,2019, 63(4):e02372-02318. [29] VIRIYAKOSOL S, KAPOOR M, OKAMOTO S, et al.APX001 and other gwt1 inhibitor prodrugs are effective in experimental Coccidioides immitis pneumonia[J]. Antimicrob Agents Chemother,2019, 63(2):e01715-01718. [30] CASTANHEIRA M, DUNCANSON F P, DIEKEMA D J, et al. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods[J]. Antimicrob Agents Chemother,2012, 56(1):352-357. [31] RIVERO-MENENDEZ O, CUENCA-ESTRELLA M, ALASTRUEY-IZQUIERDO A. In vitro activity of APX001A against rare moulds using eucast and CLSI methodologies[J]. J Antimicrob Chemother,2019, 74(5):1295-1299. [32] GEBREMARIAM T, ALKHAZRAJI S, ALQARIHI A, et al. Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to Rhizopus arrhizus[J]. Antimicrob Agents Chemother,2020, 64(6):e00178-00120. [33] ZHAO M, LEPAK A J, VANSCOY B, et al. In vivo pharmacokinetics and pharmacodynamics of APX001 against Candida spp. In a neutropenic disseminated candidiasis mouse model[J]. Antimicrob Agents Chemother,2018, 62(4):e02542-02517. [34] PFALLER M A, HUBAND M D, FLAMM R K, et al. In vitro activity of APX001A (manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program in 2017[J]. Antimicrob Agents Chemother,2019, 63(8):e00840-00819. [35] ARENDRUP M C, CHOWDHARY A, JØRGENSEN K M, et al. Manogepix (APX001A) in vitro activity against Candida auris: Head-to-head comparison of EUCAST and CLSI MICs[J]. Antimicrob Agents Chemother, 2020, 64(10):e00656-00620. [36] BERKOW E L, LOCKHART S R. Activity of novel antifungal compound APX001A against a large collection of Candida auris[J]. J Antimicrob Chemother,2018, 73(11):3060-3062. [37] ZHU Y, KILBURN S, KAPOOR M, et al. In vitro activity of manogepix against multidrug-resistant and panresistant Candida auris from the New York outbreak[J]. Antimicrob Agents Chemother,2020, 64(11):e01124-01120. [38] HODGES M R, OPLE E, SHAW K J, et al. Phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple oral doses of APX001 and to investigate the effect of food on APX001 bioavailability[J].Open Forum Infect Dis,2017, 4(Suppl_1):S534. [39] PAPPAS P, KULLBERG B J, VAZQUEZ J A, et al. Clinical safety and efficacy of novel antifungal, fosmanogepix, in the treatment of candidemia: Results from a phase 2 proof of concept trial [J].Open Forum Infect Dis, 2020, 7(Suppl 1): S203-S204. [40] BULPA P, RAHAV G, OREN I, et al.Clinical safety, efficacy, and pharmacokinetics of fosmanogepix, a novel first-in-class antifungal, in patients with renal insufficiency: subset analysis from a phase 2 candidemia trial [J].Open Forum Infect Dis, 2020, 7(Suppl 1): S605. [41] KULLBERG B B, PAPPAS L, VAZQUEZ P G, et al. Clinical efficacy and safety of the novel antifungal fosmanogepix in patients with candidaemia and/or invasive can- didiasis caused by Candida auris: results from a phase II proof of concept trial[C]//31st ECCMID. Vienna:2021. [42] OLIVER J D, SIBLEY G E M, BECKMANN N, et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase[J]. Proc Natl Acad Sci U S A,2016, 113(45):12809-12814. [43] WIEDERHOLD N P. Review of the novel investigational antifungal olorofim[J]. J Fungi (Basel),2020, 6(3):122. [44] ZHANG J, LIU H, XI L, et al. Antifungal susceptibility profiles of olorofim (formerly F901318) and currently available systemic antifungals against mold and yeast phases of Talaromyces marneffei[J]. Antimicrob Agents Chemother,2021, 65(6):e00256-00221. [45] LIM W, EADIE K, KONINGS M, et al. Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim[J]. J Antimicrob Chemother,2020, 75(4):936-941. [46] SINGH A, SINGH P, MEIS J F, et al. In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species[J]. J Antimicrob Chemother, 2021, 76(5): 1229-1233. [47] SU H, ZHU M, TSUI C K, et al. Potency of olorofim (f901318) compared to contemporary antifungal agents against clinical Aspergillus fumigatus isolates, and review of azole resistance phenotype and genotype epidemiology in China[J]. Antimicrob Agents Chemother,2021, 65(5):e02546-02520. [48] BUIL J B, RIJS A, MEIS J F, et al. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates[J]. J Antimicrob Chemother,2017, 72(9):2548-2552. [49] COLLEY T, ALANIO A, KELLY S L, et al. In vitro and in vivo antifungal profile of a novel and long-acting inhaled azole, PC945, on Aspergillus fumigatus infection[J]. Antimicrob Agents Chemother,2017, 61(5):e02280-02216. [50] RUDRAMURTHY S M, COLLEY T, ABDOLRASOULI A, et al. In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris[J]. J Antimicrob Chemother,2019, 74(10):2943-2949. [51] CASS L, MURRAY A, DAVIS A, et al. Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent[J]. Pharmacol Res Perspect,2021, 9(1):e00690. [52] KIMURA G, NAKAOKI T, COLLEY T, et al. In vivo biomarker analysis of the effects of intranasally dosed PC945, a novel antifungal triazole, on Aspergillus fumigatus infection in immunocompromised mice[J]. Antimicrob Agents Chemother,2017, 61(9):e00124-00117. [53] YATES C M, GARVEY E P, SHAVER S R, et al. Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors[J]. Bioorg Med Chem Lett,2017, 27(15):3243-3248. [54] SCHELL W A, JONES A M, GARVEY E P, et al. Fungal cyp51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds[J]. Antimicrob Agents Chemother,2017, 61(3):e01817-01816. [55] NISHIMOTO A T, WIEDERHOLD N P, FLOWERS S A, et al. In vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans[J]. Antimicrob Agents Chemother,2019, 63(6):e00341-00319. [56] SHUBITZ L F, TRINH H T, GALGIANI J N, et al. Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models[J]. Antimicrob Agents Chemother,2015, 59(12):7249-7254. [57] GEBREMARIAM T, ALKHAZRAJI S, LIN L, et al. Prophylactic treatment withVT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection[J]. Antimicrob Agents Chemother,2017, 61(9):e00390-00317. [58] BRAND S R, DEGENHARDT T P, PERSON K, et al. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis[J]. Am J Obstet Gynecol,2018, 218(6):624. [59] ELEWSKI B, BRAND S, DEGENHARDT T, et al. A phaseⅡ, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail[J]. Br J Dermatol,2021, 184(2):270-280. |
| [1] | . [J]. Chinese Journal of Mycology, 2023, 18(4): 377-380. |
| [2] | WANG Haofei, WANG Jinlong, HU Wenhan, SONG Qianwen, WU Changde, HE Jie, HU Linlin, XU Jingyuan, LI Qing, PAN Chun, XIE Jianfeng, HUANG Yingzi. Pharmacokinetic changes and influencing factors of amphotericin B in patients with severe invasive fungal infection [J]. Chinese Journal of Mycology, 2023, 18(2): 117-122. |
| [3] | . [J]. Chinese Journal of Mycology, 2023, 18(2): 172-177. |
| [4] | . [J]. Chinese Journal of Mycology, 2023, 18(2): 183-187. |
| [5] | CHAO Wen, DENG Zhongyu, GUO Shijin, GUO Yifan, YAN Lan, QIU Lijuan, LV Quanzhen. Study on the antifungal activity of small G protein inhibitor CASIN in vitro [J]. Chinese Journal of Mycology, 2022, 17(4): 289-293. |
| [6] | . [J]. Chinese Journal of Mycology, 2022, 17(4): 339-348. |
| [7] | HUANG Lei, ZHANG Yaming, YIN Cunlin, MIAO Yang, QI Wang, WANG Aming. Drug use evaluation of caspofungin based on weighted TOPSIS method [J]. Chinese Journal of Mycology, 2022, 17(3): 200-204,230. |
| [8] | . [J]. Chinese Journal of Mycology, 2022, 17(3): 235-240. |
| [9] | . [J]. Chinese Journal of Mycology, 2022, 17(3): 241-243,264. |
| [10] | . [J]. Chinese Journal of Mycology, 2022, 17(3): 247-250. |
| [11] | QIU Lijuan, CHAO Wen, SHI Anzhe, YAN Lan, LYU Quanzhen, JIANG Yuanying. Study on the synergistic antifungal activity of glyceryl monostearate and caspofungin in vitro [J]. Chinese Journal of Mycology, 2021, 16(3): 145-149,165. |
| [12] | ZHANG Xinyu, PAN Kaisu, LUO Hong, ZHENG Dongyan, ZHENG Yanqin, CAO Cunwei, LIANG Gang. In vitro susceptibility of berberine combined with antifungal agents against Talaromyces marneffei [J]. Chinese Journal of Mycology, 2021, 16(3): 176-181. |
| [13] | . [J]. Chinese Journal of Mycology, 2021, 16(3): 188-193,210. |
| [14] | Expert group of consensus on the clinical application of Terbinafine. Clinical Application of Terbinafine：Expert consensus [J]. Chinese Journal of Mycology, 2020, 15(5): 257-261. |
| [15] | ZHU Hong-mei, WEN Hai. Clinical application of terbinafine in the treatment of superficial mycosis [J]. Chinese Journal of Mycology, 2020, 15(5): 297-303. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
